BioLine RX Ltd
TASE:BLRX
Intrinsic Value
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. [ Read More ]
The intrinsic value of one BLRX stock under the Base Case scenario is 9.89 ILS. Compared to the current market price of 16 ILS, BioLine RX Ltd is Overvalued by 38%.
Valuation Backtest
BioLine RX Ltd
Run backtest to discover the historical profit from buying and selling BLRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
BioLine RX Ltd
Current Assets | 47.2m |
Cash & Short-Term Investments | 43m |
Receivables | 1.2m |
Other Current Assets | 3m |
Non-Current Assets | 16.7m |
PP&E | 1.9m |
Intangibles | 14.9m |
Current Liabilities | 30.9m |
Accounts Payable | 14.2m |
Other Current Liabilities | 16.6m |
Non-Current Liabilities | 19.9m |
Long-Term Debt | 7.9m |
Other Non-Current Liabilities | 11.9m |
Earnings Waterfall
BioLine RX Ltd
Revenue
|
4.8m
USD
|
Cost of Revenue
|
-3.7m
USD
|
Gross Profit
|
1.1m
USD
|
Operating Expenses
|
-44.1m
USD
|
Operating Income
|
-43m
USD
|
Other Expenses
|
-17.6m
USD
|
Net Income
|
-60.6m
USD
|
Free Cash Flow Analysis
BioLine RX Ltd
BLRX Profitability Score
Profitability Due Diligence
BioLine RX Ltd's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
Score
BioLine RX Ltd's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
BLRX Solvency Score
Solvency Due Diligence
BioLine RX Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
BioLine RX Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLRX Price Targets Summary
BioLine RX Ltd
According to Wall Street analysts, the average 1-year price target for BLRX is 3 ILS .
Shareholder Return
BLRX Price
BioLine RX Ltd
Average Annual Return | -35.58% |
Standard Deviation of Annual Returns | 34.41% |
Max Drawdown | -91% |
Market Capitalization | 162.5m ILS |
Shares Outstanding | 10 158 352 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact
IPO
Employees
Officers
The intrinsic value of one BLRX stock under the Base Case scenario is 9.89 ILS.
Compared to the current market price of 16 ILS, BioLine RX Ltd is Overvalued by 38%.